

Aviso de Derechos para emisoras del

FECHA: 14/10/2025



BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:

<i>FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO</i>	270437
<i>FOLIO DE REFERENCIA INDEVAL</i>	846532C003
<i>TIPO DE MENSAJE</i>	Replace
<i>COMPLETO / INCOMPLETO</i>	COMPLETE
<i>CONFIRMADO / NO CONFIRMADO</i>	CONFIRMED

<i>CLAVE DE COTIZACIÓN</i>	ZIMV
<i>RAZÓN SOCIAL</i>	ZIMVIE INC.
<i>SERIE</i>	*
<i>ISIN</i>	US98888T1079
<i>MERCADO PRINCIPAL</i>	NASDAQ

<i>TIPO DE EVENTO</i>	MERGER
-----------------------	--------

<i>MANDATORIO / OPCIONAL / VOLUNTARIO</i>	Mandatory
<i>FECHA EFECTOS</i>	21/10/2025

<i>OPCIÓN</i>	1
<i>TIPO</i>	Cash
<i>DEFAULT</i>	true

<i>TRANSACCIÓN</i>	Cash Movement
<i>CREDIT / DEBIT</i>	Credit

Aviso de Derechos para emisoras del



FECHA: 14/10/2025

TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Debit

VALORES A RECIBIR	US98888T1079

NOTAS DEL EVENTO CORPORATIVO

NOTA

13/10/2025

PALM BEACH GARDENS, Fla., Oct. 10, 2025

ZimVie Inc. announced that at the special meeting of ZimVie stockholders held on October 10, 2025, the ZimVie stockholders voted to approve the acquisition of ZimVie by an affiliate of ARCHIMED (the Merger) pursuant to the terms and conditions of the Agreement and Plan of Merger, dated as of July 20, 2025.

The parties now expect the Merger to close on October 20, 2025, subject to the satisfaction of all conditions in the Merger Agreement.

USNW ZIMVIE INC Symbol ZIMV Recent Sedar Documents ZimVie Stockholders Vote to Approve Acquisition by ARCHIMED 2025.10.1009.15 ET . News Release PALM BEACHGARDENS, Fla., Oct. 10, 2025 (GLOBENEWSWIRE) ZimVie Inc. (ZimVie) (Nasdaq. ZIMV) today announced thatat the special meeting of ZimVie stockholders held on October 10, 2025, the ZimVie stockholders voted toapprove the acquisition of ZimVie by an affiliate of ARCHIMED (the Merger) pursuant to the terms and conditions of the Agreement and Plan of Merger, dated as of July 20, 2025(the Merger Agreement). The parties now expect the Merger to close on October 20, 2025, subject to thesatisfaction of all conditions in the Merger Agreement.

04/09/2025

Notice of special meeting of stockholders to be held on October 10, 2025.

Only Company stockholders of record at the close of business on September 2, 2025 will be entitled to notice of, and to vote at, the special meeting and any postponement or adjournment thereof.

As previously announced, on July 20, 2025, the Company entered into an Agreement and Plan of Merger with Zamboni Parent Inc., a Delaware corporation and an affiliate of ARCHIMED SAS, and Zamboni MergerCo Inc., a Delaware corporation and a wholly owned subsidiary of Parent, providing for, subject to the satisfaction or waiver (to the extent permitted by applicable law) of specified conditions, the acquisition of the Company by Parent at a price of USD 19.00, without interest, per share of common stock, par value USD 0.01 per share, of the Company, issued and outstanding immediately prior to the effective time of the merger (as defined below). Subject to the terms and conditions of the merger agreement, MergerCo will be merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent. If the merger is consummated, you will be entitled to receive an amount in cash equal to USD 19.00, without interest and subject to any applicable withholding taxes, in exchange for each share of Company common stock you own at the effective time of the merger (unless you have properly and validly exercised and do not withdraw your appraisal rights under Section 262 of the General Corporation Law of the State of Delaware).

Dissenter Rights

If the merger is consummated, persons who do not wish to accept the merger consideration are entitled to seek appraisal of their shares of Company common stock under Section 262 and, if all procedures described in Section 262 are strictly complied with, to receive payment in cash for the fair value of their shares of Company common stock exclusive of any element of value arising from the accomplishment or expectation of the merger, as determined by the Delaware Court of Chancery, together with interest, if any, to be paid upon the amount determined to be the fair value.

PALM BEACH GARDENS, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED, an investment firm focused exclusively on healthcare industries.

Under the terms of the merger agreement, ZimVie stockholders will receive USD 19.00 in cash for each share of ZimVie common stock outstanding at the closing of the transaction, corresponding to an enterprise value of approximately USD 730 million.

The Board of Directors of ZimVie has unanimously approved the transaction. The transaction is expected to close by year-end 2025, subject to the satisfaction of customary closing conditions, including approval by ZimVie's stockholders and applicable regulatory

Aviso de Derechos para emisoras del

FECHA: 14/10/2025



approvals.

Under the terms of the merger agreement, ZimVie, with the assistance of Centerview Partners, its financial advisor, may solicit proposals from third parties for a period of 40 days continuing through midnight, New York City time, on August 29, 2025. ZimVie does not anticipate disclosing any developments regarding this process unless and until its Board of Directors makes a decision with respect to a potential superior proposal. There can be no assurance that the solicitation process will result in a superior proposal.